Clinical trial
Intralesional Treatment With Interleukin-2 (Proleukin) in Soft Tissue Melanoma…
NCT00204581 · University Hospital Tuebingen, Other · Completed
Key facts
| NCT number | NCT00204581 |
|---|---|
| Title | Intralesional Treatment With Interleukin-2 (Proleukin) in Soft Tissue Melanoma Metastases |
| Official title | Intralesional Treatment With Interleukin-2 (Proleukin) in Soft Tissue Melanoma Metastases. A Phase II, Prospective, Open, Multicenter Trial |
| Lead sponsor | University Hospital Tuebingen, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma |
| Intervention type | Drug |
| Interventions | Interleukin-2 (Proleukin) |
| Enrollment | 51 |
| Start date | Aug 1, 2003 |
| Primary completion | Jan 1, 2009 |
| Completion | Dec 1, 2009 |
| First posted | Sep 20, 2005 |
| Last update posted | Aug 19, 2011 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: